Abstract: Disclosed are a variety of phenethylamine-based 5-HT2AR agonists that, in silico, show higher predicted affinity than phenethylamine. The agonists of the present disclosure are expected to demonstrate therapeutic benefits in treating mental disorders. In some embodiments, the invention may comprise the use of the compounds of the present invention to treat depression, and particularly drug-resistant depression. Other conditions that may be treated include: anxiety disorders, including anxiety in advanced stage illness e.g. cancer as well as generalized anxiety disorder, depression including major depressive disorder, postpartum depression, cluster headaches, obsessive-compulsive disorder, personality disorders, including conduct disorder, drug disorders including: alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence and other addictions including gambling disorder, eating disorder and body dysmorphic disorder, chronic pain, or chronic fatigue.

Abstract: An antimicrobial material comprising a tetraalkylphosphonium ionic liquid and metal nanoparticles.

Abstract: Disclosed are a variety of structures for agonists of 5-HT2AR some of which show promise for activity greater than psilocin. The agonists of the present disclosure are expected to demonstrate therapeutic benefits to treat mental disorders. In some embodiments, the invention may comprise the use of the compounds of the present invention to treat depression, and particularly drug resistant depression. Other conditions that may be treated include: anxiety disorders, including anxiety in advanced stage illness e.g. cancer as well as generalized anxiety disorder, depression including major depressive disorder, postpartum depression, cluster headaches, obsessive compulsive disorder, personality disorders including conduct disorder, drug disorders including: alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence and other addictions including gambling disorder, eating disorder and body dysmorphic disorder, chronic pain, or chronic fatigue.

Abstract: Disclosed are various embodiments for increasing the biotransport characteristics of a psychedelic active ingredient across the mammalian blood-brain barrier. Disclosed are pharmaceutically-acceptable psychedelics that, when administered, convert to an active form in vivo, and act as a 5HT2AR agonist which are useful to treat psychiatric disorders, neurological disorders, degenerative disorders, inflammatory disorders, and symptoms thereof.

Abstract: Disclosed is a process for the manufacture of the self-nanoemulsifying drug delivery systems (SNEDDS) of the present invention by a process that comprises: (a) combining (i) a therapeutic amount of one or more tryptamine-scaffold psychedelics, (ii) a triglyceride oil, (iii) a first surfactant, (iv) a second surfactant, and, optionally, (v) an anti-oxidant in a container, (b) adding a lower chain alcohol to said container while mixing the ingredients therein to form a pre-emulsion product, (c) optionally cooling said pre-emulsion product, and (d) diluting the pre-emulsion product with water to form a self-nanoemulsifying drug delivery system.